Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits

Introduction Pyrotinib is a novel irreversible pan-HER tyrosine kinase inhibitor (TKI). However, real-world data of pyrotinib-containing therapy in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and developing brain metastases (BMs) are limited, and the genomic profile of this subpopulation is almost undefined. Methods and materials Patients with BM of HER2-positive MBC (n = 35) treated with pyrotinib-containing therapy were enrolled in this analysis. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and toxicity profiles were evaluated. Hazard ratios (HRs) and 95% confidence intervals (CIs) for disease progression were estimated using the Cox proportional hazards models. Targeted next-generation sequencing of 618 cancer-relevant genes was performed on plasma and primary breast tumors from patients with BM and without BM. Results The median PFS time was 8.00 (95% CI, 5.98–10.017) months, and the median OS time was 23 (95% CI, 10.412–35.588) months. The ORR was 45.7%, and the DCR was 74.3%. In the Cox multivariate analysis, prior exposure to brain radiotherapy (HR = 3.268), received pyrotinib as third- or higher-line treatment (HR = 4.949), subtentorial brain metastasis (HR = 6.222), and both supratentorial and subtentorial brain metastases (HR = 5.863) were independently associated with increased risk of progression. The frequent grade 3–4 adverse event was increased direct bilirubin (14.3%), and two patients suffered from grade 3–4 diarrhea. In the exploratory genomic analysis, altered frequencies of FGFR3, CD276, CDC73, and EPHX1 were higher in the BM group. The consistency of mutated profiles of plasma and primary lesion in the BM group was significantly lower (30.4% vs. 65.5%; p = 0.0038). Conclusions Pyrotinib-containing therapy shows favorable effectiveness and tolerable safety in patients with BM of HER2-positive MBC, particularly in a population that is brain radiotherapy-naïve, received pyrotinib as first- or second-line treatment, and developed supratentorial brain metastasis. In the exploratory genomic analysis, patients with BM showed distinct genomic features from patients without BM.

[1]  M. Kudo,et al.  Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study. , 2023, Journal of Clinical Oncology.

[2]  Qiong-wen Zhang,et al.  Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study , 2023, Frontiers in Pharmacology.

[3]  X. Bai,et al.  Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial , 2022, Breast Cancer Research and Treatment.

[4]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis , 2022, Cancer discovery.

[5]  T. Szekeres,et al.  Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial , 2022, Nature Medicine.

[6]  A. Toga,et al.  A quantitative characterization of the spatial distribution of brain metastases from breast cancer and respective molecular subtypes , 2022, Journal of Neuro-Oncology.

[7]  S. Rajkumar,et al.  Treatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches , 2022, Diagnostics and therapeutics.

[8]  S. Chandarlapaty,et al.  Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Awada,et al.  Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis , 2022, ESMO open.

[10]  A. Jacobson Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer , 2022, The oncologist.

[11]  Ming Yan,et al.  Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. , 2022, The Lancet. Oncology.

[12]  P. Brown,et al.  Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Loi,et al.  Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  E. Zhou,et al.  Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data , 2021, Clinical Cancer Research.

[15]  L. Pusztai,et al.  Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. , 2021, The oncologist.

[16]  N. Ibrahim,et al.  Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Ying Cheng,et al.  Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[18]  A. Giannoudis,et al.  The genomic landscape of breast cancer brain metastases: a systematic review. , 2021, The Lancet. Oncology.

[19]  H. Yao,et al.  Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study , 2020 .

[20]  C. Anders,et al.  HER2‐positive breast cancer brain metastasis: A new and exciting landscape , 2020, Cancer reports.

[21]  P. Ellis,et al.  Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  E. Winer,et al.  Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Souweidane,et al.  B7–H3 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors , 2019, Translational oncology.

[24]  Wei Li,et al.  Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Bertucci,et al.  A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases , 2019, Cancers.

[26]  E. Winer,et al.  TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Gnant,et al.  Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases , 2019, Clinical Cancer Research.

[28]  Xin Li,et al.  Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[29]  A. Bardelli,et al.  Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases , 2017, ESMO Open.

[30]  Peng Yuan,et al.  Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Adrian V. Lee,et al.  Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases , 2017, JAMA oncology.

[32]  Xiaoyan Chen,et al.  Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[33]  A. Viale,et al.  Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  T. Agatsuma,et al.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.

[35]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[36]  K. Blackwell,et al.  Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  K. Blackwell,et al.  Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Yun-di Guo,et al.  B7-H3 expression in breast cancer and upregulation of VEGF through gene silence , 2014, OncoTargets and therapy.

[39]  H. Iwata,et al.  Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis , 2014, Breast Cancer Research and Treatment.

[40]  S. Duffy,et al.  Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer , 2013, Breast Cancer Research.

[41]  M. Westphal,et al.  Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. , 2013, The American journal of pathology.

[42]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[43]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[44]  H. Harputluoglu,et al.  Breast cancer subtypes and outcomes of central nervous system metastases. , 2011, Breast.

[45]  Cyrus Chargari,et al.  Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. , 2011, International journal of radiation oncology, biology, physics.

[46]  H. Rugo,et al.  Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER , 2011, Clinical Cancer Research.

[47]  L. Crinò,et al.  Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Baselga,et al.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  B. Leyland-Jones Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Greil,et al.  Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer , 2009, Clinical Cancer Research.

[52]  M. Milella,et al.  Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials , 2008, Breast Cancer Research and Treatment.

[53]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  N. F.,et al.  Long Survival in a Patient with Brain Metastases from Breast Cancer , 2008, Clinical medicine. Oncology.

[55]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[56]  J. Mackey,et al.  Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  C. Platini,et al.  Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. , 2006, The Lancet. Oncology.

[58]  R. Gelber,et al.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  E. Winer,et al.  Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  C. Szczylik,et al.  Central nervous system metastases in breast cancer patients administered trastuzumab. , 2005, Cancer treatment reviews.

[61]  A. Howell,et al.  Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer , 2004, British Journal of Cancer.

[62]  OUP accepted manuscript , 2022, The Oncologist.

[63]  L. Lou,et al.  Discovery and development of pyrotinib : A novel irreversible EGFR / HER 2 dual tyrosine kinase inhibitor with favorable safety pro fi les for the treatment of breast cancer , 2017 .

[64]  W. Gradishar,et al.  Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  M. Campone,et al.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.

[66]  E. Winer,et al.  Ten years of HER2-directed therapy: still questions after all these years , 2008, Breast Cancer Research and Treatment.